Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography

Inclusion Criteria:

• Histologic diagnosis of nasopharyngeal carcinoma or NSCLC
• With an evaluable secondary malignant neoplasm of Liver, diameter≥2cm
• Without transcatheter arterial chemoembolization (TACE) treatment
• Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.
• Estimated life expectancy of at least 3 months
• Patient compliance and geographic proximity that allow adequate follow-up.
• Adequate organ function including the following: Bone marrow: absolute neutrophil count (ANC) >or= 1.5x10^9/L, platelets >or= 100x10^9/L, hemoglobin >or= 9g/dL. Hepatic: bilirubin <1.5 x ULN, alkaline phosphatase, aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5 x ULN (alkaline phosphatase, AST, ALT < 5 x ULN is acceptable if liver has tumor involvement). Renal: calculated creatinine clearance > 45 ml/min.
• Men or women of at least 18 years of age.
• Signed informed consent from patient.

Exclusion Criteria:

• Women who are pregnant or in lactation
• Systemic treatment for another cancer within the year prior to study entry
• Known hypersensitivity to any of the study drugs or to drugs with similar chemical structures
• Use of investigational agents within 28 days of the Baseline visit, or participating simultaneously in any other clinical studies
• Severe co-morbidity of any type that may interfere with assessment of the patient for the study